Home » Stocks » NAVB

Navidea Biopharmaceuticals, Inc. (NAVB)

Stock Price: $2.38 USD -0.07 (-2.86%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 67.16M
Revenue (ttm) 815,061
Net Income (ttm) -11.15M
Shares Out 25.84M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $2.38
Previous Close $2.45
Change ($) -0.07
Change (%) -2.86%
Day's Open 2.44
Day's Range 2.33 - 2.50
Day's Volume 310,000
52-Week Range 0.63 - 5.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 month ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 1 month ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Seeking Alpha - 3 months ago

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q3 2020 Results - Earnings Call Transcript

Business Wire - 3 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 3 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 3 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Zacks Investment Research - 3 months ago

Navidea (NAVB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 4 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 4 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 4 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Seeking Alpha - 5 months ago

Navidea Biopharmaceuticals: Too Many Risks Involved

Business Wire - 5 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 5 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents an...

Business Wire - 6 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and...

Seeking Alpha - 6 months ago

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript

Business Wire - 6 months ago

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and...

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Navidea Biopharmaceuticals (NAVB) stock based on the movements in the options market lately.

Forbes - 8 months ago

Retail sales surging 18% in May fared well with the markets this morning, but with growing concerns over a Coronavirus resurgence, it's clear that volatility is just around the corner. We've u...

Other stocks mentioned: ARCB, ECOR, FLNT, GRUB
GlobeNewsWire - 8 months ago

DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodia...

GlobeNewsWire - 8 months ago

  Live Video Moderated Discussion with CEO, Jed Latkin, to be Held on Tuesday, June 16th, at 2:00 PM ET, Immediately Followed by an Interactive Q&A Session

Forbes - 8 months ago

Many believe that the market does not accurately the current state of our economy. With double-digit unemployment and Q2 earnings expected to disappoint, the stock market is rich with several ...

Other stocks mentioned: BLNK, LQDA, SVRA
GlobeNewsWire - 8 months ago

DUBLIN, Ohio, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development ...

24/7 Wall Street - 9 months ago

Navidea Biopharmaceuticals Inc. (NYSE: NAVB) shares more than doubled to close out the week after the company provided an update from its midstage study in patients with active rheumatoid arth...

Market Watch - 9 months ago

Shares of Navidea Biopharmaceuticals Inc. NAVB, -1.55% more than doubled in very active premarket trading Friday, after the company provided upbeat data on an ongoing phase 2 trial of its trea...

Seeking Alpha - 9 months ago

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 11 months ago

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Navidea Biopharmaceuticals' (NAVB) CEO Jed Latkin on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

For real-time updates on NAVB, beat the news and login or try Benzinga Pro. Biotechnology company that specializes in precision medicine, Navidea Biopharmaceuticals Inc (NYSE: NAVB) today had ...

Seeking Alpha - 1 year ago

Navidea Biopharmaceuticals (NAVB) CEO Jed Latkin on Q1 2019 Results - Earnings Call Transcript

About NAVB

Navidea Biopharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages. Its CD206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), ima... [Read more...]

Industry
Biotechnology
IPO Date
Nov 10, 1992
CEO
Jed Latkin
Employees
13
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NAVB
Full Company Profile

Financial Performance

In 2019, NAVB's revenue was $657,826, a decrease of -43.74% compared to the previous year's $1.17 million. Losses were -$10.95 million, -32.06% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NAVB stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 215.13% from the latest price.

Price Target
$7.50
(215.13% upside)
Analyst Consensus: Buy